Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.

Biomedicines · 2024 · PMC11428590 · PMID 39335457

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

In contrast, dulaglutide and icodec had less pronounced effects, with dulaglutide’s 1.5 mg dose showing a borderline significant increase in discontinuation rates (RR 1.48, 95% CI: 0.98 to 2.24), while its 0.75 mg dose and icodec did not show statistically significant increases.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.